Retractable Technologies, Inc. (AMEX: RVP), a leading maker of
safety needle devices, announced today that Queensland Health, a
department within the Queensland government, has awarded Retractable a
one-year contract to supply its VanishPoint(R) automated retraction
syringes to all of Queensland Health's 202 acute care facilities. The
contract, which is effective immediately and renewable for two years,
follows a successful two-year clinical study at Princess Alexandra
Hospital in Brisbane, Australia, Queensland's capital. Virtually all
of the healthcare facilities in Queensland and in Australia's five
other states are government-operated.
VanishPoint(R) products are distributed in Australia by
Brisbane-based Scientific Educational Supplies Pty Ltd.
Retractable Technologies, Inc. manufactures and markets
VanishPoint(R) automated retraction safety syringes and blood
collection devices, which virtually eliminate health care worker
exposure to accidental needlestick injuries. These revolutionary
devices use a patented friction ring mechanism that causes the
contaminated needle to retract automatically from the patient into the
barrel of the device, a feature that is designed to prevent reuse.
VanishPoint(R) safety needle devices are distributed by various
specialty and general line distributors. For more information on
Retractable, visit our Web site at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant
to the safe harbor provision of the Private Securities Litigation
Reform Act of 1995 and reflect the Company's current views with
respect to future events. The Company believes that the expectations
reflected in such forward-looking statements are accurate. However,
the Company cannot assure you that such expectations will materialize.
The Company's actual future performance could differ materially from
such statements.
Factors that could cause or contribute to such differences
include, but are not limited to: the impact of dramatic increases in
demand; the Company's ability to maintain and quickly increase its
production capacity in the event of a dramatic increase in demand; the
Company's ability to access the market; the Company's ability to
decrease production costs; the Company's ability to continue to
finance research and development as well as operations and expansion
of production; the increased interest of other larger market players,
specifically Becton Dickinson and Company, Inc., in providing safety
needle devices to their customers; and other risks and uncertainties
that are detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission.
